Latest News:- Hypoparathyroidism Market: Parathyroid hormone is expected to lead the Product segment during 2024-2028

Hypoparathyroidism Market to grow at a CAGR of 7.6% during 2024-2028

The Hypoparathyroidism Market is expected to grow at a CAGR of 7.6% during 2023 and 2028. During this period, the market is also expected to show a growth of USD 474.9 million. The global hypoparathyroidism market is experiencing a significant shift towards inorganic growth strategies, as demonstrated by recent high-profile acquisitions. Notably, AstraZeneca announced a definitive agreement to acquire Amolyt Pharma in March 2024, a clinical-stage biotech specializing in rare endocrine diseases. This strategic move bolsters AstraZeneca's Alexion Rare Disease pipeline, specifically in the bone metabolism sector. The acquisition of Amolyt Pharma brings a promising addition to AstraZeneca's portfolio in the form of eneboparatide (AZP-3601), a Phase III investigational therapeutic peptide. Eneboparatide's novel mechanism of action targets crucial therapeutic goals for hypoparathyroidism, making it a valuable asset for AstraZeneca in addressing this rare endocrine disorder. 

Get more information on Hypoparathyroidism Market by requesting a sample report

The Parathyroid hormone subsegment is expected to dominate the Product segment during the forecast period 

Technavio analysts predict that the Parathyroid hormone subsegment will lead the Product segment during 2024 and 2028 The global hypoparathyroidism market is experiencing significant growth, driven primarily by the advancement of Parathyroid Hormone (PTH) therapies. Despite a recent setback with the FDA's rejection, the European Commission approved YORVIPATH in November 2023, a novel treatment for chronic hypoparathyroidism. This condition is characterized by parathyroid gland dysfunction leading to deficient PTH secretion, resulting in hypocalcemia, hyperphosphatemia, and increased neuromuscular irritability. Patients may experience symptoms such as muscle pain (myalgias), spasms, twitching, and in severe cases, seizures and tetany, due to low calcium levels and hormone deficiency duration.

Here are the various ways based on which the market is segmented: 

• Product
  • Parathyroid hormone
  • Vitamin D analogue
  • Calcium supplement
  • Others
• Distribution Channel
  • Hospital pharmacy
  • Retail pharmacy
  • Online pharmacy
• Geography
  • North America
  • Europe
  • Asia
  • Rest of World (ROW)

Reasons to Purchase the Global Hypoparathyroidism Market Market Research Report by Technavio. What is in it for you?

• Wealth of Experience: Technavio is an established name in the world of market research. It holds an expertise of more than 20 years in the field, has published 21,000+ reports thereby extensively covering the area in various industries and range of regions
• Insight into Current Market Trends: Our research reports provide our readers insights into the latest market intelligence, competitor strategies, market trends, changes taking place in the industry and customer preferences, forecasted market opportunities that influence them to make better business decisions
• High ROI with Extensive Hands-on Research: Technavio is renowned for offering personalized market research reports as per unique business needs, delving deep into specific markets, product segments and demographics. Additionally, it is also well-known for providing high return on investments through its wide collection of data at pocket-friendly rates

There are several factors that are causing the market to flourish increased awareness programs for thyroid treatment

Learn which are the obstacles that the market is experiencing in the way of its growth by accessing the free PDF report

Research Analysis Overview

Hypoparathyroidism is a rare endocrine disorder characterized by decreased production of parathyroid hormone (PTH), leading to low calcium and high phosphorus levels in the body. Diagnosis is based on low serum calcium levels, high plasma PTH, and albumin-corrected total calcium levels. Causes include autoimmune destruction, genetic conditions, and complications from thyroidectomy. Hospital Pharmacy and specialty centers play a crucial role in managing hypoparathyroidism through various treatments. Surgery, such as thyroidectomy, may be necessary for some patients. Postoperative complications include low serum magnesium and calcium levels. Medications like hormonal therapy, vitamin D analogues, calcium supplements, and phosphate binders are commonly used to manage the condition. Calcitriol is a commonly prescribed medication for hypoparathyroidism. Homecare and parenteral nutrition may be required for severe cases. The hypoparathyroidism treatment market is expected to grow due to the increasing number of cases, especially idiopathic and hereditary forms. The market includes various players offering oral and injectable medications, homecare services, and hospital-based treatments. The market growth is driven by the increasing prevalence of endocrine disorders and the development of new treatments.

Market Research Overview

The global pharmaceuticals market encompasses businesses involved in the research and development (R&D) or production of various types of drugs, including generics, non-generics, and veterinary drugs. According to Technavio, the healthcare industry market size is determined by the collective revenue generated by manufacturers and providers of medical equipment, supplies, pharmaceuticals, biotechnology, and life sciences tools and services. Factors driving the expansion of the pharmaceuticals market include the increasing global population aging, with the US projecting that over 25% of its population will be over 60 years old by 2050, and Europe reaching a similar demographic milestone by 2030.

The Hypoparathyroidism Market is experiencing significant growth, fueled by the increased awareness programs for thyroid treatment. Industries are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/